These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36752338)

  • 21. Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies.
    Patel P; Shrivastava SK; Sharma P; Kurmi BD; Shirbhate E; Rajak H
    J Biomol Struct Dyn; 2024; 42(1):362-383. PubMed ID: 36995068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligand-based pharmacophore modeling of TNF-α to design novel inhibitors using virtual screening and molecular dynamics.
    Jade DD; Pandey R; Kumar R; Gupta D
    J Biomol Struct Dyn; 2022 Mar; 40(4):1702-1718. PubMed ID: 33034255
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Chowrasia D; Jafri A; Azad I; Rais J; Sharma N; Khan F; Kumar A; Kumar S; Arshad M
    J Biomol Struct Dyn; 2022 Nov; 40(18):8569-8586. PubMed ID: 33955334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploration and evaluation of bioactive phytocompounds against BRCA proteins by
    Prabhavathi H; Dasegowda KR; Renukananda KH; Lingaraju K; Naika HR
    J Biomol Struct Dyn; 2021 Sep; 39(15):5471-5485. PubMed ID: 32643536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemical Characterization,
    Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
    Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
    Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
    J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of novel monoamine oxidase B (MAO-B) inhibitors by combined application of docking-based alignment, 3D-QSAR, ADMET prediction, molecular dynamics simulation, and MM_GBSA binding free energy.
    El Aissouq A; Chedadi O; Bouachrine M; Ouammou A; Khalil F
    J Biomol Struct Dyn; 2023 Jul; 41(10):4667-4680. PubMed ID: 35510607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Silico and In Vitro Screening of 50 Curcumin Compounds as EGFR and NF-κB Inhibitors.
    Saeed MEM; Yücer R; Dawood M; Hegazy MF; Drif A; Ooko E; Kadioglu O; Seo EJ; Kamounah FS; Titinchi SJ; Bachmeier B; Efferth T
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure based virtual screening, 3D-QSAR, molecular dynamics and ADMET studies for selection of natural inhibitors against structural and non-structural targets of Chikungunya.
    Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
    J Biomol Struct Dyn; 2019 Aug; 37(12):3150-3161. PubMed ID: 30114965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV.
    Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
    J Biomol Struct Dyn; 2019 Jan; 37(1):131-146. PubMed ID: 29268664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
    Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
    Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
    Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
    Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies.
    Gupta S; Singh AK; Kushwaha PP; Prajapati KS; Shuaib M; Senapati S; Kumar S
    J Biomol Struct Dyn; 2021 Aug; 39(12):4334-4345. PubMed ID: 32476576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
    Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
    J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
    Zaka M; Abbasi BH; Durdagi S
    J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
    Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
    Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer.
    Anbuselvam M; Easwaran M; Meyyazhagan A; Anbuselvam J; Bhotla HK; Sivasubramanian M; Annadurai Y; Kaul T; Pappusamy M; Balasubramanian B
    J Biomol Struct Dyn; 2021 Aug; 39(12):4462-4471. PubMed ID: 32567493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening.
    Sirous H; Campiani G; Calderone V; Brogi S
    Comput Biol Med; 2021 Oct; 137():104808. PubMed ID: 34478925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.